Osmotic Wearable Bolus Injector (oWBI) for viscous drug delivery

Informazioni relative al progetto

oWBI

ID dell’accordo di sovvenzione: 808021

DOI

10.3030/808021

Progetto chiuso

Data della firma CE 20 Gennaio 2018

Data di avvio 1 Febbraio 2018

Data di completamento 30 Aprile 2018

Finanziato da

• INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT)

Costo totale

€ 71 429,00

Contributo UE

€ 50 000,00

Coordinato da

SUBCUJECT APS
Denmark

Periodic Reporting for period 1 - oWBI (Osmotic Wearable Bolus Injector (oWBI) for viscous drug delivery)

Periodo di rendicontazione: 2018-02-01 al 2018-04-30

Sintesi del contesto e degli obiettivi generali del progetto

There is a continuous growth of drugs coming onto the market as combination products (drug products paired with delivery devices). Pharmaceuticals are paying closer attention to integrated delivery systems, especially Wearable Bolus Injectors (WBIs) for patients subcutaneously (SC) self-administrating a large dose of medication.

Intravenous (IV) drug administration in healthcare facilities is costly, being estimated that 30-70% savings are obtained if the same therapy is self-administered SC. Furthermore, it is rapidly increasing the number of biologic therapeutics demanding delivery of large (>2ml) and highly viscous doses that must be injected slowly over minutes rather than seconds. These two facts support the strong need for WBIs.

oWBI main goal is to complete the development cycle of the Subcuject device platform (a disruptive WBI for subcutaneous self- administration of drugs) and implement the necessary business-related activities to overcome the remaining barriers for rapid and efficient market uptake.

Lavoro eseguito dall’inizio del progetto fino alla fine del periodo coperto dalla relazione e principali risultati finora ottenuti

During the feasibility study, we have interviewed several pharma companies and other stakeholders. We performed the following tasks: (1) Market analysis: Investigation of the SC delivery systems market (main competitors, reimbursement policies, end-user profiling, etc). The most promising and low risk class drugs to bundle with Subcuject were identified. (2) Modular design refinement. (3) Certification and regulatory requirements analysis. (4) IPR strategy definition: 2 patents were filled and a Freedom to Operate analysis carried out - no IPR roadblocks were identified. (5) Business plan elaboration. (6) Plan the innovation project (Phase 2), incl. formal engagement of partners for the demonstration activities.

Progressi oltre lo stato dell’arte e potenziale impatto previsto (incluso l’impatto socioeconomico e le implicazioni sociali più ampie del progetto fino ad ora)

The outcome of this innovation project will include the following advantages: (1) Cost-effectiveness (production price 75-86% lower than competitive solutions). (2) Flexibility and versatility through a modular design allowing different dosage amounts and dosing time. (3) Can be refrigerated due to the absence of electronics. (4) Eco-friendly / Sustainable. (5) Intuitive and user friendly. (6) Discretion and comfort.

Subcuject’s impact and benefits reach not only the customers (Pharma companies) and end-users (Patients) but also other players across the supply chain/value chain, such as payers, prescribes and the overall society.

Subcuject concept and its Unique Selling Points